tiprankstipranks
Trending News
More News >

Cleo Diagnostics Highlights Ovarian Cancer Detection Progress Amid Share Price Surge

Story Highlights
  • Cleo Diagnostics is advancing clinical trials for its Ovarian Cancer detection technology.
  • The company is uniquely positioned as the only ASX-listed entity focused on Ovarian Cancer diagnostics.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cleo Diagnostics Highlights Ovarian Cancer Detection Progress Amid Share Price Surge

Confident Investing Starts Here:

CLEO Diagnostics Ltd ( (AU:COV) ) has shared an announcement.

Cleo Diagnostics Ltd responded to an ASX price query regarding the recent increase in its share price, highlighting its high-performing Ovarian Cancer detection technology currently in clinical trials for FDA approval. The announcement coincides with the start of Ovarian Cancer Awareness Month, emphasizing the company’s unique position as the sole ASX-listed entity focused on this critical women’s health issue.

More about CLEO Diagnostics Ltd

Cleo Diagnostics Ltd is a medical technology company listed on the ASX, specializing in the development of a blood test for the early diagnosis of Ovarian Cancer. The company focuses on creating simple and accurate diagnostic solutions and is actively engaged in clinical trials in the U.S. to secure FDA approval.

YTD Price Performance: 1.39%

Average Trading Volume: 56,330

Technical Sentiment Consensus Rating: Strong Sell

See more insights into COV stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App